|
gptkbp:instanceOf
|
gptkb:chemical_compound
|
|
gptkbp:approvalYear
|
1984
|
|
gptkbp:ATCCode
|
gptkb:N07BB04
|
|
gptkbp:bioavailability
|
5-40% (oral)
|
|
gptkbp:CASNumber
|
16590-41-3
|
|
gptkbp:contraindication
|
liver failure
acute hepatitis
|
|
gptkbp:drugClass
|
opioid
|
|
gptkbp:eliminationHalfLife
|
4 hours
|
|
gptkbp:excretion
|
renal
biliary
|
|
gptkbp:hasInChIKey
|
LZIQPTQZZIFGSV-UHFFFAOYSA-N
|
|
gptkbp:hasMolecularFormula
|
C17H19NO3
|
|
gptkbp:hasPharmacologicalAction
|
treatment of alcohol dependence
treatment of opioid dependence
|
|
gptkbp:hasSMILES
|
C1CC1CN2CCC3C4CCC(=O)C4(C2)CC5=C3C=CC(=C5)O
|
|
gptkbp:hasUNII
|
2S7953Q994
|
|
gptkbp:hasWikipediaPage
|
https://en.wikipedia.org/wiki/Naltrexone
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
CHEMBL43016
|
|
gptkbp:indication
|
alcohol dependence
opioid dependence
|
|
gptkbp:IUPACName
|
(4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-dihydroxy-2,3,4,4a,5,6,7,7a-octahydro-1H-benzo[f]isoquinolin-7-one
|
|
gptkbp:legalStatus
|
prescription only
off-patent
|
|
gptkbp:manufacturer
|
various generic manufacturers
|
|
gptkbp:mechanismOfAction
|
opioid
|
|
gptkbp:MeSH_ID
|
D009325
|
|
gptkbp:metabolism
|
hepatic
|
|
gptkbp:molecularWeight
|
285.34
|
|
gptkbp:pregnancyCategory
|
C (US)
B3 (Australia)
|
|
gptkbp:proteinBinding
|
21%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL43016
5360515
DB00704
CHEBI:7459
|
|
gptkbp:routeOfAdministration
|
oral
intramuscular
|
|
gptkbp:sideEffect
|
nausea
dizziness
fatigue
headache
|
|
gptkbp:status
|
approved
|
|
gptkbp:synonym
|
gptkb:Naltrexone
|
|
gptkbp:target
|
gptkb:delta-opioid_receptor
gptkb:kappa-opioid_receptor
gptkb:mu-opioid_receptor
|
|
gptkbp:therapeuticArea
|
addiction medicine
|
|
gptkbp:bfsParent
|
gptkb:2,3,7,8-tetrachlorodibenzo-p-dioxin
|
|
gptkbp:bfsLayer
|
8
|